Fan Yihua, Wen Xinyan, Zhang Qiang, Wang Fangyuan, Li Qing, Li Xinju, Guo Yi
Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
The First Teaching Hospital of Tianjin University of TCM, Tianjin 300193, China.
Evid Based Complement Alternat Med. 2020 Feb 7;2020:3439457. doi: 10.1155/2020/3439457. eCollection 2020.
This systematic review and meta-analysis aimed at evaluating the effect of traditional Chinese medicine (TCM) Bufei granule on stable chronic obstructive pulmonary disease (COPD). We retrieved data from PubMed, Web of Science, EMBASE, the Cochrane Central Register of Controlled Trials, CNKI, Wanfang, and WeiPu (VIP) for studies focusing on whether the TCM Bufei granule would be effective in treating stable COPD. No language restriction and blinding were used. All trials involved were examined based on the standards of the Cochrane Handbook, and Review Manager 5.3 software was applied for analyzing data. We included four studies involving 599 patients with stable COPD. When compared to placebo treatment, TCM Bufei granule intervention exhibited improvement in the forced expiratory volume in one second (FEV) (standardized mean difference (SMD) = 0.70; range, 0.50-0.91; = 0%), forced vital capacity (FVC) (SMD = 0.43; range, 0.23-0.62; = 0%), FEV percentage of predicted value (FEV1%) (SMD = 0.57; range, 0.38-0.76; = 4%), and FEV/FVC (SMD = 0.69; range, 0.50-0.87; = 0%). There was a statistically significant difference in St George's Respiratory Questionnaire scores between the TCM Bufei granule and placebo treatments (SMD = -1.29; range, -2.32 to -0.26, = 97%). None of the studies reported any adverse events. Therefore, TCM Bufei granule intervention could help in improving the lung function and quality of life in patients with stable COPD.
本系统评价和荟萃分析旨在评估中药补肺颗粒对稳定期慢性阻塞性肺疾病(COPD)的疗效。我们从PubMed、科学网、EMBASE、Cochrane对照试验中心注册库、中国知网、万方和维普(VIP)检索数据,以查找关注中药补肺颗粒治疗稳定期COPD是否有效的研究。未设置语言限制和盲法。所有纳入的试验均按照Cochrane手册标准进行审查,并应用Review Manager 5.3软件进行数据分析。我们纳入了4项研究,共599例稳定期COPD患者。与安慰剂治疗相比,中药补肺颗粒干预可改善一秒用力呼气容积(FEV)(标准化均数差(SMD)=0.70;范围为0.50 - 0.91;P = 0%)、用力肺活量(FVC)(SMD = 0.43;范围为0.23 - 0.62;P = 0%)、FEV占预计值百分比(FEV1%)(SMD = 0.57;范围为0.38 - 0.76;P = 4%)以及FEV/FVC(SMD = 0.69;范围为0.50 - 0.87;P = 0%)。中药补肺颗粒与安慰剂治疗在圣乔治呼吸问卷评分上存在统计学显著差异(SMD = -1.29;范围为-2.32至-0.26,P = 97%)。所有研究均未报告任何不良事件。因此,中药补肺颗粒干预有助于改善稳定期COPD患者的肺功能和生活质量。